GlassScriptPhysician profile
Stephanie Levine
NPI 1912548751
$4,133.77
in general payments reported to CMS, 2019-2025
32 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $795 · 2022: $1,304 · 2023: $349 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $597.87 | 2021-2022 | |
| Janssen Biotech, INC. | $495.75 | 2021-2023 | Tremfya |
| Axsome Therapeutics, INC. | $458.67 | 2025 | Auvelity |
| Janssen Scientific Affairs, LLC | $346.97 | 2021-2022 | |
| Abbvie INC. | $253.32 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.73 | 2025 | Caplyta |
| Amgen INC. | $241.59 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $234.29 | 2025 | Cobenfy |
| Alkermes, INC. | $160.61 | 2025 | Lybalvi, Aristada |
| Lilly USA, LLC | $157.12 | 2021-2025 | Amyvid, Kisunla |
| Tris Pharma INC | $145.94 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Teva Pharmaceuticals USA, INC. | $135.64 | 2025 | Austedo Xr |
| Incyte Corporation | $108.75 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $66.85 | 2022 | |
| Biogen, INC. | $54.09 | 2025 | Vumerity |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $46.02 | 2025 | Vyepti, Rexulti |
| Regeneron Healthcare Solutions, INC. | $40.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.18 | 2025 | Trintellix |
| Neurocrine Biosciences, INC. | $30.69 | 2025 | |
| Luye Pharma (USA) LTD. | $30.45 | 2025 | Erzofri Extended-Release |
| Leo Pharma INC. | $26.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $25.94 | 2021 | |
| Collegium Pharmaceutical, INC. | $23.72 | 2025 | Jornay Pm |
| Sebela Pharmaceuticals INC. | $22.51 | 2021 | |
| Organogenesis INC. | $21.58 | 2022 | |
| Noven Therapeutics, LLC | $21.56 | 2025 | Secuado, Xelstrym |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.38 | 2021 | |
| Pfizer INC. | $18.49 | 2022 | |
| Genzyme Corporation | $18.35 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.84 | 2021 | |
| Genentech USA, INC. | $13.56 | 2025 | Ocrevus Zunovo |
| Sun Pharmaceutical Industries INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.